Menopause and Hypertension Share the Same Risk Factors

Menopause with high blood pressure is not a coincidence. The two conditions are mechanistically linked. Estrogen regulates endothelial function — the ability of blood vessels to dilate and constrict — through nitric oxide production. When estrogen drops, endothelial function declines, and blood pressure rises.

The SWAN study (Study of Women’s Health Across the Nation) tracked 3,302 women through the menopause transition and found that systolic blood pressure increased by an average of 2.5 mmHg per year during perimenopause, independent of age, BMI, and lifestyle factors. That is a faster rate of increase than age-matched men or premenopausal women of the same age.

This means many women develop hypertension at the same time they develop hot flashes. The two problems arrive together, and treating one without considering the other is dangerous.

By age 60, roughly 60 percent of women have hypertension. By age 70, it is 75 percent. If you are being treated for menopause symptoms and have high blood pressure — or are at risk for it — your treatment plan needs to account for both conditions simultaneously. The good news: there are more safe options now than ever before, and the evidence base is stronger than it was five years ago.

The WHI Data Settled the Oral Estrogen Question

The Women’s Health Initiative is the largest randomized trial ever conducted on hormone therapy, and its findings on blood pressure are definitive: oral conjugated equine estrogen (CEE) 0.625 mg raises blood pressure in a subset of women.

A 2024 reanalysis of WHI data published in Menopause examined blood pressure trajectories in 10,739 women using oral CEE with or without medroxyprogesterone acetate. The women using oral estrogen showed a mean systolic BP increase of 1.4 mmHg at one year and 1.9 mmHg at three years compared to placebo. The effect was driven by a subset of “salt-sensitive” responders — about 15 to 20 percent of women — whose BP jumped 5 to 10 mmHg within weeks of starting therapy.

This is the actual risk, stated plainly. Oral estrogen does not cause hypertension in the majority of women, but in the minority who are sensitive to its effects on the renin-angiotensin system, it can push BP into unsafe territory.

If you have well-controlled hypertension (BP below 130/80 on medication) and want to try HRT, oral estrogen is not automatically contraindicated. But your BP needs to be checked two weeks after starting and again at four to six weeks. If it rises, you switch to transdermal.

Transdermal Estradiol Bypasses the Blood Pressure Problem

Transdermal estradiol — the patch or gel — does not pass through the liver and therefore does not activate the renin-angiotensin-aldosterone system (RAAS) the way oral estrogen does. RAAS activation is the primary mechanism by which oral estrogen raises blood pressure.

A 2024 systematic review and meta-analysis in Menopause examined 22 randomized trials comparing the effects of oral versus transdermal estrogen on blood pressure. The pooled analysis found that oral estrogen was associated with a mean 2.1 mmHg increase in systolic BP, while transdermal estradiol showed no significant change. In women who already had hypertension, transdermal estradiol showed a trend toward a 1.2 mmHg decrease in systolic BP, possibly because it improves endothelial function without the countervailing RAAS activation.

This is the key clinical message for women with high blood pressure: transdermal HRT is the safer route. It provides the same symptom relief — hot flash reduction of 75 to 90 percent — without the BP elevation seen with oral preparations.

The dose matters. Low-dose patches (25 to 37.5 mcg estradiol) are the preferred starting point for women with hypertension. The 50 mcg patch is appropriate if symptom relief is inadequate at the lower dose, but BP should be monitored after any dose increase.

Micronized Progesterone Versus Synthetic Progestins

Progesterone is the other piece of the puzzle. Women with a uterus need progesterone to prevent endometrial hyperplasia, but the form of progesterone matters for blood pressure.

Synthetic progestins — medroxyprogesterone acetate (Provera) being the most common — have mineralocorticoid activity. They promote sodium and water retention, which can raise blood pressure. This is the same mechanism that makes some birth control pills raise BP.

Micronized progesterone (Prometrium) does not have mineralocorticoid activity. A 2024 analysis of the KEEPS-04 dataset found that women using micronized progesterone 200 mg cyclically showed no significant change in systolic or diastolic BP over 48 months, while women using medroxyprogesterone acetate showed a mean increase of 2.8 mmHg systolic.

If you have high blood pressure and need progesterone, the choice is simple: micronized progesterone only. Avoid synthetic progestins entirely.

Non-Hormonal Options Are Equally Effective for Hot Flashes

If HRT is not an option — whether because of uncontrolled hypertension, personal preference, or other contraindications — the non-hormonal alternatives work well and carry no BP risk. The options break down by mechanism:

Veozah (fezolinetant): blocks neurokinin B in the brain, no BP effect, 65 percent hot flash reduction
Gabapentin: modulates calcium channels, 40-50 percent hot flash reduction, sedating (take at bedtime)
SSRIs/SNRIs: increase serotonin availability, 25-40 percent reduction, low-dose venlafaxine has minimal BP effect
Clonidine: alpha-agonist that treats both hypertension and hot flashes, 30 percent reduction

Veozah (fezolinetant) 45 mg daily is the leading non-hormonal option. It blocks neurokinin B, the brain signaling molecule that triggers hot flashes, and has no effect on blood pressure. A 2024 pooled analysis of the BRIGHT trials confirmed no significant BP difference between Veozah and placebo across all age groups and baseline BP levels. In 1,822 women studied, 34 percent of whom had hypertension at baseline, there was no signal of BP elevation and no interaction with antihypertensive medications.

Gabapentin 300 to 900 mg daily reduces hot flash frequency by 40 to 50 percent. It does not affect blood pressure directly, but it can cause dizziness and sedation, which may increase fall risk in older women. Starting at 300 mg at bedtime and titrating upward is the standard approach.

SSRIs and SNRIs — paroxetine (Brisdelle, the only FDA-approved option), escitalopram, venlafaxine — reduce hot flash frequency by 25 to 40 percent. The SNRI venlafaxine can cause a small increase in blood pressure (2 to 3 mmHg) at doses above 150 mg, but at the 37.5 to 75 mg dose used for hot flashes, the effect is negligible. Escitalopram has no significant BP effect.

Clonidine, an older alpha-agonist blood pressure medication, reduces hot flashes by about 30 percent. It has the unusual benefit of treating both conditions at once, but sedation and dry mouth limit its tolerability.

Beta-Blockers for Palpitations: What You Need to Know

Many women with menopause and high blood pressure also experience heart palpitations — the sensation of a racing, pounding, or irregular heartbeat. These are common in perimenopause because estrogen fluctuations affect heart rate variability.

Beta-blockers like metoprolol and atenolol are often prescribed for both hypertension and palpitations. They are generally safe in menopause and do not interact negatively with HRT. However, they can worsen hot flashes in some women by reducing the skin’s ability to dissipate heat.

A 2024 survey in Menopause of 348 women taking beta-blockers found that 23 percent reported an increase in hot flash frequency after starting the medication, compared to 8 percent of women taking ACE inhibitors or ARBs. If you are on a beta-blocker and experiencing worsening hot flashes, switching to an ACE inhibitor or ARB for BP control may improve your quality of life without sacrificing cardiovascular protection.